Empagliflozin in Patients Admitted to Hospital With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Lancet Diabetes Endocrinol 2023 Oct 18;[EPub Ahead of Print], RECOVERY Collaborative GroupFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.